Your browser is no longer supported. Please, upgrade your browser.
EDSA [NASD]
Edesa Biotech, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own4.40% Shs Outstand10.28M Perf Week-5.80%
Market Cap74.22M Forward P/E- EPS next Y-1.84 Insider Trans1.02% Shs Float6.46M Perf Month13.83%
Income-7.90M PEG- EPS next Q-0.29 Inst Own14.90% Short Float0.84% Perf Quarter-15.59%
Sales0.20M P/S371.12 EPS this Y-34.10% Inst Trans-15.09% Short Ratio0.19 Perf Half Y6.75%
Book/sh0.77 P/B7.81 EPS next Y-72.00% ROA-84.10% Target Price- Perf Year119.35%
Cash/sh- P/C- EPS next 5Y- ROE-118.10% 52W Range2.46 - 19.10 Perf YTD41.41%
Dividend- P/FCF- EPS past 5Y21.60% ROI-97.00% 52W High-68.53% Beta0.65
Dividend %- Quick Ratio- Sales past 5Y-15.40% Gross Margin93.70% 52W Low144.30% ATR0.50
Employees12 Current Ratio8.50 Sales Q/Q- Oper. Margin- RSI (14)52.53 Volatility8.20% 9.35%
OptionableNo Debt/Eq0.00 EPS Q/Q-76.00% Profit Margin- Rel Volume0.39 Prev Close5.87
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume285.68K Price6.01
Recom- SMA203.49% SMA507.62% SMA200-2.63% Volume110,689 Change2.39%
May-14-21 08:00AM  
Apr-22-21 08:00AM  
Mar-26-21 11:14AM  
03:10AM  
Mar-22-21 07:45AM  
Mar-15-21 08:10AM  
Mar-09-21 06:30AM  
Mar-02-21 04:10PM  
Feb-25-21 10:20PM  
05:12PM  
Feb-17-21 05:07AM  
Feb-16-21 07:30AM  
Feb-02-21 12:15PM  
Jan-26-21 07:30AM  
Jan-20-21 07:45AM  
Jan-11-21 07:30AM  
Dec-30-20 08:00AM  
Dec-10-20 05:36AM  
Dec-08-20 01:18AM  
Dec-07-20 07:45AM  
Nov-30-20 07:30AM  
Nov-06-20 08:00AM  
Nov-03-20 07:25AM  
Oct-19-20 07:30AM  
Aug-31-20 05:00PM  
Aug-21-20 04:02PM  
05:55AM  
Aug-12-20 07:45AM  
Jul-30-20 07:45AM  
Jun-15-20 08:15AM  
May-27-20 07:20AM  
May-19-20 06:47AM  
May-15-20 08:00AM  
Apr-24-20 08:35AM  
Apr-20-20 09:00AM  
Apr-02-20 10:33AM  
Mar-12-20 07:30AM  
Feb-13-20 04:10PM  
Jan-06-20 09:21AM  
Dec-12-19 04:30PM  
Dec-03-19 07:30AM  
Nov-05-19 07:30AM  
Oct-21-19 07:30AM  
Aug-29-19 08:30AM  
Aug-14-19 04:05PM  
Jul-25-19 07:30AM  
Jun-20-19 12:12PM  
08:26AM  
07:30AM  
07:30AM  
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brooks Michael JPresidentMar 25Buy5.193,50018,16513,241Mar 26 11:44 AM
Nijhawan PardeepChief Executive OfficerMar 25Buy5.253,00015,750545,312Mar 26 11:44 AM
Nijhawan PardeepChief Executive OfficerMar 24Buy5.165,00025,800542,312Mar 25 02:43 PM
OAKES FRANK R.DirectorFeb 18Sale7.251,82713,2460Feb 18 07:40 PM
OAKES FRANK R.DirectorFeb 18Sale7.256,16544,6960Feb 18 07:40 PM
Brooks Michael JPresidentMay 27Buy3.002,5007,4984,327May 29 09:20 AM
Nijhawan PardeepChief Executive OfficerMay 26Buy2.983,0008,9392,124,024May 28 12:19 PM